# vTv Therapeutics Posts a $0.94 Q3 GAAP Loss Per Share, 15 Cents Better Than Estimate

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50877
Published: 2026-11-07T14:32:53.000Z
Updated: 2026-11-07T14:32:53.000Z
Section: Business

> Cash and cash equivalents were $77.2 million on Sept. 30, 2026, compared with $88.9 million on Dec. 31, 2025.

vTv Therapeutics Inc. (NASDAQ: VTVT) posted a third-quarter GAAP loss of $0.94 per share, beating the estimate by 15 cents, while cash and cash equivalents stood at $77.2 million on Sept. 30, 2026.

The company had $88.9 million in cash and cash equivalents on Dec. 31, 2025.